European Society for Medical Oncology Congress

ESMO 2026

  1. Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study
  2. ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers
  3. Aulos Bioscience’s Imneskibart With Avelumab Delivers Exceptional Progression-Free Survival in Checkpoint Inhibitor-Refractory Adenocarcinoma Non-Small Cell Lung Cancer
  4. BioInvent’s BI-1808 and KEYTRUDA® Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer
  5. BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
  6. Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer
  7. Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer
  8. Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation
  9. Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
  10. Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented
  11. Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful ORR in Patients with Metastatic Colorectal Cancer
  12. Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  13. Imdelltra® In Combination With Imfinzi® Reduced Risk Of Death By An Unprecedented 58% In First-Line Extensive Stage Small Cell Lung Cancer
  14. ImmVira Presents Clinical Data from Three Bladder Cancer Studies
  15. Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
  16. Innovent Presented Phase 1 Study Data for IBI3001
  17. Iovance Presents New Data Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
  18. Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
  19. Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
  20. KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
  21. Leads Biolabs’ LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data, Validating Its Proprietary TCE Platform
  22. Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
  23. Merck and Moderna Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) 
  24. NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
  25. New data on Lilly’s investigational treatment olomorasib show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
  26. NovaBridge Biosciences Reports Mature Phase 1b Data Positioning Givastomig for Registrational Development
  27. KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
  28. Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
  29. MEDSIR presents final TUXEDO-3 results highlighting the potential of patritumab deruxtecan in active brain metastases and leptomeningeal disease
  30. Oncolytics Biotech® Presents REO 033 Trial in Progress Abstract Showcasing Pelareorep’s Potential in Colorectal Cancer
  31. Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
  32. Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
  33. Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented
  34. Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101
  35. Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented
  36. Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC and Highlights Pan-KRAS Progress
  37. Results of CARsgen’s Satri-cel for Adjuvant Treatment for Gastric Cancer Presented
  38. Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer
  39. Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers
  40. Ris-Rez reduced risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma in China
  41. Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
  42. Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
  43. Sonesitatug vedotin reduced the risk of death by 42% in 2nd- and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
  44. Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
  45. Tagrisso plus Orpathys reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on Tagrisso
  46. Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in OS and PFS in Phase 3 Advanced Gastric Cancer Study
  47. Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
  48. VHIO Presents New Precision Oncology Options for Patients with Thyroid Cancer
  49. Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
  50. Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b
  51. Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191

Share:

Read more